NAPRT and lymphoma: It was shown that the lack of NAPRT expression in some tumors, such as neuroblastoma, glioblastoma (183) or lymphomas (184), puts NAPRT as a biomarker for the use of Na as a chemoprotectant agent during treatment with NAMPT inhibitors (126).